Compare CVCO & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVCO | MMED |
|---|---|---|
| Founded | 1965 | 1983 |
| Country | United States | United States |
| Employees | 7000 | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 1994 | 2026 |
| Metric | CVCO | MMED |
|---|---|---|
| Price | $454.90 | $10.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $550.00 | $22.56 |
| AVG Volume (30 Days) | 108.0K | ★ 582.9K |
| Earning Date | 05-21-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.74 | N/A |
| EPS | ★ 18.55 | N/A |
| Revenue | ★ $2,142,713,000.00 | N/A |
| Revenue This Year | $14.66 | $15.99 |
| Revenue Next Year | $7.70 | $10.00 |
| P/E Ratio | $24.80 | ★ N/A |
| Revenue Growth | ★ 31.68 | N/A |
| 52 Week Low | $393.53 | $10.65 |
| 52 Week High | $713.01 | $17.86 |
| Indicator | CVCO | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 33.90 |
| Support Level | $455.66 | N/A |
| Resistance Level | $604.08 | $15.80 |
| Average True Range (ATR) | 19.33 | 0.69 |
| MACD | -4.26 | -0.01 |
| Stochastic Oscillator | 17.79 | 17.22 |
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.